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In the European Union, sponsors have the responsibility to demonstrate the “intention to diagnose, prevent or
treat” a serious and rare condition before the Committee of Orphan Medicinal Products (COMP), for a medicinal
product to meet the criteria for Orphan Designation. This requirement is commonly referred to as “medical
plausibility” and the justification of this intention is assessed on the merits of each application by the COMP, which
deliberates over the scientific evaluation of the evidence submitted. The scientific assessment of the applications for
orphan designation by the Committee is based on the review of non-clinical (such as in vitro and in vivo) and/or
clinical data submitted by the sponsor. Several challenges regarding the evidence provided emerge when the
sponsor is applying for a designation at an early stage of development. Herein we discuss specific examples from
the experience of the COMP, in order to elaborate on the type and level of evidence generally considered necessary
for the purpose of justification of the intention to treat an orphan condition. Importantly, it is pointed out that
bridging of data from other products, irrespectively of how comparable they may be, or from settings not directly
associated with the condition as applied for designation, is by and large not a successful exercise and may only
be exceptionally considered. It is further exemplified that, as reflected in the updated ‘Guideline on the format and
context of the applications for designation’ and the guidance document ‘Recommendation on elements required to
support the medical plausibility and the assumption of significant benefit for an orphan designation’ available on the
EMA website, the sponsor should provide data with the specific product as applied for in specific models of the
condition or in patients affected by the same condition subject of each application.Background
In order to incentivise the development of medicinal
products for rare conditions that would not otherwise
attract attention by the pharmaceutical industry, a Euro-
pean framework for “orphan medicinal products” has
been put in place for more than a decade now. The
Committee of the Orphan Medicinal Products (COMP)
of the European Medicines Agency (EMA) evaluates the
applications for Orphan Medicinal Product designation
in the EU. The criteria for orphan designation in the EU
are described in Article 3 of Regulation (EC) No. 141/
2000 [1]. As per the first paragraph of Article 3(1) of the* Correspondence: Stylianos.Tsigkos@ema.europa.eu
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medicine shall be designated as an orphan medicinal
product if its sponsor can establish: “that it is intended
for the diagnosis, prevention or treatment of a life-
threatening or chronically debilitating condition affecting
not more than five in 10 thousand persons in the Com-
munity when the application is made (…)”.
In the EU orphan regulatory practice, this intention to
diagnose, prevent or treat is also referred to as “medical
plausibility”, and as such cited in the respective guide-
line, which expects data to be presented by the sponsors
to confirm the feasibility of the proposal [2,3]. In this
manuscript the terms “intention to treat”, as appearing
in the orphan regulatory jargon and “medical plausibil-
ity” are used interchangeably. The reader is advised not
to confuse this “intention to diagnose, prevent or treat”Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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clinical trials.
To justify medical plausibility before the COMP, the
sponsor has to present data from studies with the prod-
uct which support the promise of a relevant effect in the
specific condition proposed for designation. Providing
data of this nature is not always straightforward, given
that the medicinal product may be at an early stage of
development and the data comes from non-clinical
models which are difficult to interpret [4]. Indeed, Art-
icle 5 specifies “In order to obtain the designation of a
medicinal product as an orphan medicinal product, the
sponsor shall submit an application to the Agency at any
stage of the development of the medicinal product before
the application for marketing authorisation is made”.
A “tug-of war” may therefore be conceptualised be-
tween the need for data to support the criteria for either
diagnosis, prevention or treatment of the condition on
the one hand, and the provisions allowing sponsors to
seek designations at very early developmental stages on
the other, thereby relying on results that need extrapola-
tion and acceptance of pharmacological assumptions in
the assessment process by the COMP.
Since 2000 [5], the issue of medical plausibility has
been extensively deliberated and has evolved into a firm
practice of the data requirements associated with estab-
lishing medical plausibility. This is reflected in the fourth
revision of the Guideline on the Format and Content of
Application ENTR6283/00 Rev 04 2014 [2]. Under the
medical plausibility section on page 6, it is stated, “In
order to support the rationale for the development of the
product in the proposed condition preliminary preclinical
or some clinical data are generally required. It is import-
ant to include, as far as possible, a discussion of the re-
sults of pre-clinical studies with the specific product, as
applied for in the specific condition, and/or a discussion
on preliminary clinical data in patients affected by the
condition. Where available, reports of studies from the
sponsor and supporting the use of the product in the ap-
plied condition should be included in the orphan desig-
nation application. The aim, methodology, results of all
relevant studies, etc., should be submitted at the time of
the application”.
Since September 2012 the EMA, following its policy
on transparency, started to publish the COMP meeting
minutes. This manuscript discusses some orphan desig-
nation cases which have been discussed in the published
minutes found on the Agency’s website, with the
intention to provide hands-on examples that may help
future sponsors and interested parties to understand the
data requirements for the justification of medical plausi-
bility. This is without pre-empting the COMP’s remit to
discuss each application on the basis of its own scientific
merits.Methods
Case studies from the COMP procedures of the year 2013
The published minutes of the year 2013 [5] were reviewed
for examples of data submitted for the evaluation and out-
come of medical plausibility for the purpose of Orphan
Medicinal Product Designation. This year was chosen for
most current examples that would reflect the evolved
standards in the consideration of medical plausibility, as
also reflected in the recently updated guideline [2].
The starting point for selecting examples was the
consolidated experience on the common issues raised
during the procedures of the COMP, with regards to jus-
tification of medical plausibility. These issues were used
as the basis to form the categories for the purpose of
this paper, as outlined below. The categories were then
populated by case studies from the published minutes,
and several excerpts from these minutes are also in-
cluded in the discussion [5].
It has to be noted that the selected examples focus ex-
clusively on the issues associated with data submitted
for the purpose of establishing the medical plausibility
issues and not any other orphan criteria. The sponsors,
in addition to the medical plausibility, have to justify that
all criteria of the orphan Regulation are met; neverthe-
less, those rest outside of the scope of this paper. It is fi-
nally stressed that the cited examples were selected
merely on the basis of clarity, simplicity and educational
usefulness for demonstrating the points of this reflection
and not on the base of any other merit and could have
been equally replaced by other examples.
Results
Examples of successful justification of medical plausibility
Justification based on preclinical data
Preclinical data have been used in establishing medical
plausibility within the context of an orphan medicinal
product designation. The scientific rationale for use of
the product in the applied condition is to be elucidated
as far as possible. In this type of submissions the most
decisive points within the framework of the evaluation
process are:
 the relevance of models used, and
 the relevance of endpoints studied.
The models used should replicate the features of the
medical condition as closely as possible, in order to
allow for extrapolations to be made and to draw conclu-
sions for the condition as applied for designation. It
follows that early preclinical studies, such as in vitro
studies alone, would be more difficult to interpret than
higher level studies such as those performed in validated
animal models of disease. As per the COMP recommen-
dation paper on elements required to support the medical
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(EMA/COMP/2009) ‘at least relevant in vitro and in vivo
data in appropriate preclinical models should be submit-
ted’, stressing the need for adequate studies to have been
performed in animal models [3]. Only exceptionally may
in vitro data be considered as a sole basis, and as per the
same recommendation paper “if in vitro studies only is
available…the relevance of the findings should be dis-
cussed in the context of the proposed condition”. For
example, in the case of a well-known condition and a
well-known class of products, in vitro data in cell lines
might be considered supportive.
Moreover, the endpoints chosen in the preclinical
studies should also be relevant to the clinical target
sought, thereby aiding evaluators to make a meaningful
assessment of relevant improvements secondary to the
pharmacological intervention.
The relevance of models used and the relevance of
endpoints studied, should therefore be viewed as neces-
sary prerequisites for any application in support for
medical plausibility. It is important to point the differ-
ence between applications based on scientific hypothesis
where a products’ mode of action in the target condition
is presented with support from a generic scientific ra-
tionale on the one hand, and applications based on data
with the proposed medicine in a relevant model of the
condition and endpoints which are indicative of effect.
This is reflected in the following examples [5].
Case 1. High altitude pulmonary oedema
High Altitude Pulmonary Oedema is a life-threatening
form of non-cardiogenic pulmonary oedema that de-
velops in susceptible people who ascend quickly from
low to high altitude, typically above 2.500 meters [6]. Its
pathophysiology remains unclear, but low partial pres-
sure of oxygen at high altitude causes excessive hypoxic
vasoconstriction, inadequate ventilatory response to hyp-
oxia, and leak or stress failure of the pulmonary capillaries.
It remains the major cause of death related to high-
altitude exposure, with a high mortality rate in the
absence of adequate emergency treatment [6,7]. High
altitude pulmonary oedema is a rare condition in the
European Union with an estimated incidence of less
0.03 in 10,000 people [7].
In an application for the treatment of high altitude
pulmonary oedema, the Committee was presented with
studies of the candidate product in preclinical models,
which recapitulated specific features of the condition.
Relevant in vivo non-clinical studies included a mouse
alveolar flooding model and a rat high altitude pulmon-
ary oedema model. Available data from these preclinical
studies showed increased alveolar clearance, as well as
progressive recovery of relevant functional parameters in-
cluding dynamic lung compliance and airway resistance.Because of the relevance of both models used, which reca-
pitulated aspects of the pathophysiology of the condition,
and the outcomes studied, the medical plausibility was
considered justified.
Case 2. Niemann pick
Niemann-Pick is a group of lysosomal lipid storage dis-
orders, with visceral and neurological manifestations. A
recent peer review [8] divides this condition into two en-
tities: i) acid sphingomyelinase-deficient disease resulting
from mutations in the SMPD1 gene (encompassing type A,
B and intermediate forms), and ii) Niemann-Pick disease
type C (including also type D), resulting from mutations in
either the NPC1 or the NPC2 gene. Niemann-Pick type C
has been considered by the COMP to be affecting approxi-
mately 0.1 in 10,000 people in the EU [5].
Two applications have received a positive opinion in
2013 for the treatment of Niemann-Pick type C (NPC).
In one application, the sponsor discussed relevant stud-
ies in preclinical settings including the NPC1−/− mouse
model [9]. The NPC1−/− model is a well characterised
mouse model for NPC: the pathology comprises accu-
mulation of cholesterol and glycosphingolipids and the
brain, liver and spleen are affected, while the affected
mice die at approximately 11 weeks. In this model, treat-
ment resulted in lower levels of glycosphingolipids in
the brain and liver compared to the untreated controls,
as well as inhibition of the accumulation of unesterified
cholesterol in the liver and kidney. In addition to these
biochemical markers, improved motor performance as
per rearing activity scoring and gait analysis was re-
ported. For the second application, medical plausibility
was considered acceptable based on data generated in
the same NPC1−/− mouse model, as well as in a feline
model of the condition, in cats with a spontaneously oc-
curring missense mutation in NPC1 gene [10]. The feline
model of NPC has been characterized and is phenotypic-
ally, morphologically, and biochemically similar to human
NPC1 [11]. In that model treatment showed even im-
provements in neurological symptoms and survival.
In both cases, the relevance of the models used and
the endpoints for the actual clinical entity under review,
allowed for the medical plausibility to be established.
Case 3. Duchenne Muscular Dystrophy (DMD)
Duchenne muscular dystrophy (DMD) is an X-linked
inherited disorder characterized by progressive muscle
weakness, wasting and degeneration. Although the gene
affected in DMD was identified over 25 years ago, there
is still no effective treatment [12] and the condition has
been designated in the European Union as a chronically
and seriously debilitating condition affecting approxi-
mately 0.5 in 10,000 people [5]. Most children affected
by the condition will need a wheel chair before 12 years
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reduced forced vital capacity of the lungs, requiring ven-
tilation support. Death occurs at median age of 25 years,
usually due to respiratory or cardiac failure.
Applications for the treatment of DMD based on rele-
vant preclinical models, such as the dystrophin-null mdx
dystrophic mouse model, are common [13]. In fact, all
three applications that received a positive opinion in
2013 included data from studies using the mdx mouse
model. With regards to the considered endpoints, in one
successful designation case, the sponsor submitted data
showing improved grip strength and inflammation in the
mdx mouse model. In another, improvements in lean
muscle mass and grip strength was presented to the Com-
mittee. In a third successful case in 2013, the sponsor pre-
sented studies in the mdx model, showing improvements
in muscle strength, histology and inflammation; moreover
the sponsor also included data in a double knockout mur-
ine model (dKO) of utrophin and dystrophin, showing im-
proved muscle strength and histology, while treatment
also improved lifespan of animals.
Again the COMP, having considered both the validity
of the models and the clinical relevance of the endpoints
studied, considered that the intention to treat DMD had
been justified by the respective sponsors.Justification based on applications including preliminary
clinical data
While orphan designation based on solely preclinical
data is possible at early stages of development, the
level of assumption may be reduced when successful
preliminary clinical studies are included in the appli-
cation. The degree of assumption is still considerable,
taking into account that properly conducted clinical
studies may not be available or feasible at that point in
time and that confirmation of efficacy is not required
at this stage. In applications defended on the grounds
of preliminary clinical data, the discussion revolves
around the population studied in terms of representa-
tivity for the applied disease, other treatments that
may be received by the patients, the design and in
particular the availability of controls, the endpoints
assessed and the relevance of the results observed in
the treated patients. Before considering such data, the
possibility for placebo effects, spontaneous recovery of
patients or critical bias is always scrutinized. The ra-
tionale to use the product in the applied condition
with regards to the mechanism of action should also
be elucidated as far as possible. The examples dis-
cussed below illustrate that if a sponsor can show
clinically relevant improvements in even a limited
number of treated patients, the intention to treat may
be considered justified.Case 4. Adenonsine-deaminase deficient severe combined
immunodeficiency (ADA-SCID)
Severe combined immunodeficiencies (SCID) are a group
of diseases caused by monogenic disorders that impair
T-cell development and can be associated with faults in
the development of other hematopoietic lineages [14]. At
least ten different molecular causes have been described;
deficiency of adenosine deaminase (ADA), an enzyme of
the purine salvage pathway, accounts for up to 20% of the
total number of cases [14].
It is difficult to distinguish between the different forms
of SCID on the basis of clinical presentation alone. Chil-
dren with SCID lack immune protection from infections
and are prone to repeated and persistent bacterial, viral
and fungal infections that can be very serious or life-
threatening. In its most severe form, ADA-SCID is fatal
within the first year of life. In the EU ADA-SCID has been
estimated to affect less than 0.1 in 10,000 people [5].
In an example of an application for the treatment of
ADA-SCID with a gene therapy product, the sponsor pre-
sented both preclinical and clinical studies. The in vitro
studies showed ADA expression in CD34+ cells from pa-
tients as a result of treatment, while in vivo the product
was shown to engraft in valid pre-clinical models of the
disease which used the ADA−/− mouse model and the
NSG/NOD/SCID/gamma c−/− mice, resulting in expres-
sion of ADA by immune cells. Moreover, the compassion-
ate use of the product in patients with severe ADA-SCID
resulted in effective gene transduction and in T cell recov-
ery and metabolic correction to the date of application for
designation, at 6 months of observation. Based on these
preclinical data in relevant models of the condition and
preliminary clinical data in affected patients showing rele-
vant outcomes, the medical plausibility was considered
justified for the purpose of orphan designation. The well-
defined mode-of-action allowed the consideration even of
case reports for the justification of medical plausibility.
Case 5. Eosinophilic oesophagitis
Eosinophilic esophagitis is a chronic immune-mediated
condition where infiltration of eosinophils into the
esophageal mucosa leads to esophageal dysfunction
[15]. It is a rare condition previously designated by the
COMP with a prevalence of less than 5 in 10,000
people in the EU [5].
In an application for eosinophilic esophagitis, the
intention to treat the condition with the medicinal prod-
uct was considered justified based on clinical trials
showing histologic response and reduction of symptoms
in adult and paediatric patients treated with the product.
Several trials were discussed from the available literature,
which were supplemented by sponsor-generated data
from a phase I and an on-going phase II study showing
histological remission in affected patients. In a second
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fied based on preclinical and preliminary clinical data
from a small randomised controlled trial in adult pa-
tients with the target condition, showing reduction of
eosinophil numbers in the oesophageal mucosa. This ef-
fect was considered clinically relevant as the condition is
characterised by eosinophilic inflammation.
Case 6. Epidermolysis bullosa
Epidermolysis bullosa (EB) is a heterogeneous group of
inherited skin diseases characterized by increased skin
fragility and variable degrees of extra-cutaneous presen-
tations. The four major types are simplex EB, dystrophic
EB, junctional EB, and Kindler syndrome [16]. The se-
verity of the condition ranges from localized blisters and
erosions to debilitating deformities and severe gastro-
intestinal involvement.
The COMP has considered that EB is chronically de-
bilitating and life-threatening, and affecting less than 0.8
in 10,000 persons in the European Union [5].
In an application for the treatment of EB, the sponsor
defended the medical plausibility on preliminary clinical
observations from compassionate use programs and a
small study of eight patients. In the latter setting, the
sponsor reported favourable outcomes in the wound
healing of EB patients. The sponsor further supported
its position by preclinical literature data on the general
effects of the product in wound healing.
As per the published minutes, the Committee dis-
cussed whether the results from other wounds can be
extrapolated to the specific condition subject of the ap-
plication, and whether the clinical data presented could
be considered without a clear pharmacological target for
the product. The Committee was of the view that the ex-
trapolation using not exactly the same product but an-
other formulation with different concentrations of the
active substance than the one proposed was of limited
value. In addition, with regard to the clinical studies, the
course of the condition is reported to “cycle”, i.e. there is
a loss of efficacy of skin care products after longer use.
The initial response of the patients in the uncontrolled
setting may therefore have been observed simply be due
to the change of product.
Despite these reservations, it was acknowledged that
the sponsor was developing a specific product and there
were clinical observations that support the activity of the
product in the context of treatment of EB. This was con-
sidered sufficient at that stage to support the medical
plausibility in the context of an orphan designation.
Case 7. Glioma
Glioma is a CNS neoplasm arising from glial cells and in-
cludes several subtypes depending on the type of cells that
give rise to the pathology. Malignant glioma comprisesglioblastoma (WHO grade IV), anaplastic astrocytoma
(grade III), mixed anaplastic oligoastrocytoma (grade III)
and anaplastic oligodendroglioma (grade III), with glio-
blastoma carrying the worst prognosis [17]. Glioma has
been the subject of a plethora of applications for orphan
designations and the COMP has previously considered
that the condition is chronically debilitating, in particular
due to compression and invasion of the surrounding brain
structures leading to neurological deficits, and life-
threatening with poor overall survival, which in particular
for glioblastoma multiforme patients is less than 5% at
5 years post diagnosis. The condition was estimated to be
affecting less than 3 in 10,000 persons in the European
Union [5].
In an orphan designation procedure discussed for the
treatment of glioma in 2013, the sponsor defended the
medical plausibility on both preclinical and preliminary
clinical data. In the preclinical setting, the sponsor stud-
ied the effects of the product in murine models that
have been xeno-transplanted with glioma cell lines. In
these models, tumour growth was inhibited by treatment
with the compound. In addition, as for the preliminary
clinical studies, the sponsor discussed a Phase 1 dose-
escalation study in patients with recurrent malignant gli-
oma and showed responses with regards to tumour size.
The COMP therefore accepted the medical plausibility
based on both preclinical and clinical data.Examples of unsuccessful efforts to justify medical
plausibility
As reflected in the updated guideline on the format and
content of applications for orphan medicinal product
designation [2], the data required for the demonstration
of medical plausibility should be “as far as possible spe-
cific for the proposed product and the proposed condi-
tion, either in relevant models or in patients affected by
the specific condition”.
In the absence of such data the applications remain
by large unsuccessful, because bridging to data from
other settings increases the assumption level and
weakens medical plausibility. Only exceptionally, if ob-
jective limitations can be documented, as in the case
where cross-species specificities necessitate the use of
a non-human surrogate product to be used in models
of the condition, the committee has considered such
extrapolations.
The examples discussed below exemplify the principle
that in the absence of data generated with the product
in the condition as applied for designation, orphan status
is considered difficult to be granted. It is to be noted
that the publicly available information on these proce-
dures is more limited [5] compared to the examples dis-
cussed above, because of confidentiality issues.
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Case 8. Alagille syndrome
Alagille syndrome is an autosomal dominant disorder
associated with dysfunction of the liver, heart, spine, and
eyes, which is also characteristic by a distinctive facial
appearance in many patients. It is associated with the
defect in component of the Notch signaling pathway,
with mutations in JAG1 (type 1) or NOTCH2 (type 2)
[18]. The main clinical features are chronic cholestasis
due to paucity of intrahepatic bile ducts, congenital
heart disease primarily affecting the pulmonary outflow
tract and vasculature, “butterfly” vertebrae or other ab-
normal vertebral segmentation, characteristic faces with
a broad forehead, and ophthalmic disorders such as pos-
terior embryotoxon, anterior segment abnormalities, and
retinopathy. Additional features are intracranial bleeding
and dysplastic kidneys. The diagnosis is essentially clin-
ical, and therapy is focused on the consequences of liver
disease, as well as the surgical and medical treatment of
congenital heart defects [19].
In the context of orphan designation, the condition
has been previously considered by the Committee to be
chronically debilitating due to hepatic and cardiac dys-
function. Portal hypertension develops in up to one third
of patients and life expectancy is in most cases is around
20 years and death is associated with liver failure, cardiac
problems and blood vessel abnormalities. The condition
has been estimated to be affecting not more than 0.3 in
10,000 persons in the European Union [5].
As reflected in the published minutes, in an applica-
tion of a product for the treatment of Alagille syndrome,
the Committee considered the available preclinical in vivo
data to support the intention to treat, as presented by the
application, pertained mainly to another surrogate product
(even though with the same mechanism of action) which
could not be directly extrapolated to draw conclusions for
the specific condition under evaluation. Therefore the data
were not considered appropriate to justify the medical
plausibility.
Case 9. Schnitzler’s syndrome
Schnitzler's syndrome is a disorder characterized by re-
current fever and urticarial rash, muscle bone or joint
pain, lymphadenopathy and monoclonal gammopathy. It
is considered as a paradigm of an auto-inflammatory
syndrome, of which fewer than 250 patients known, even
though the number is probably higher [20].
In the case of a medicinal product proposed for
Orphan Designation for the treatment of Schnitzler’s
syndrome, the applicant did not present data with their
own product in relevant settings but attempted bridging
to data obtained with other products having the same
mechanism of action. Having identified this limitation,
the COMP invited the sponsor to present data of theirown investigations with the product, in a pre-clinical
model or in a preliminary clinical setting in the condi-
tion. The sponsor eventually withdrew the application.
Bridging to non-relevant models, or other conditions
Case 10. Recurrent HCV infection in liver transplant
recipients
In recurrence of hepatitis C virus (HCV) infection fol-
lowing liver transplantation, the progression in the allo-
graft is more severe and develops faster compared to
other HCV infection settings. In the context of accept-
ability as an orphan condition by the COMP, this dif-
ference has been previously considered as salient for
discerning recurrence in transplant recipients from
other HCV infections.
About one third of HCV-infected recipients have de-
veloped allograft cirrhosis due to HCV recurrence by
the 5th-7th year post-transplantation [21]. In several
previous cases, the COMP has considered that recur-
rence of HCV infection in liver transplant recipient was
affecting less than 0.1 in 10,000 persons in the European
Union, and confirmed the chronically debilitating and
life-threatening nature of the condition, in particular
due to hepatic complications including cirrhosis and he-
patocellular carcinoma [5].
In a COMP procedure discussed in 2013, a sponsor
initially proposed a product for orphan designation for
prevention of recurrent HCV infection in liver trans-
plant recipients. The application was based on data
stemming from studies in the context of treatment of
chronic HCV infection, and not from studies in the con-
dition as applied for designation, which was treatment of
recurrent HCV infection in liver transplant recipients
Having examined the application, the Committee con-
sidered that recurrence of HCV in liver transplant recip-
ients is a distinct population compared to chronic HCV
infection in non-transplant recipients, and because of
this, the biochemical endpoints discussed did not allow
for an extrapolation to the sought indication as applied
for designation. Thus the medical plausibility was not
considered acceptable in the absence of data in relevant
settings.
Inadequate results in relevant settings
Interestingly, even if appropriate settings and endpoints
are used, the results obtained in the studies of an orphan
designation dossier may still be difficult to interpret. The
actual results obtained remain the major decisive factor
in the evaluation of medical plausibility. Some points are
of particular importance: first, the extent of effects
caused by the product may be limited, putting into ques-
tion the clinical relevance of the proposed intervention.
Second, the uncontrolled nature of some studies, as not
infrequently presented to the COMP in early development
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logical products. This is particularly difficult in the context
of a weakly defined mechanism of action of the product or
a potentially fluid course and phenotypic variability of the
clinical condition. Third, administration of the product in
combination with other products further complicates the
generated observations. This is exemplified in the case
discussed below.
Case 11. Fragile-X syndrome
Fragile X syndrome is considered to be the most com-
mon cause of intellectual disability and autistic spectrum
disorders [22]. The condition is caused by transcriptional
silencing of the FMR1 gene. The product of this gene,
FMRP, is an RNA-binding protein, which is theorised to
have a critical role in targeting neurospecific mRNAs to
brain synapses and inhibiting protein synthesis in re-
sponse to synaptic stimulation signals [23]. Largely based
on work in the fmr1 knockout mouse model, the condi-
tion has emerged as a disorder of synaptic plasticity
associated with abnormalities of long-term depression and
long-term potentiation and immature dendritic spine archi-
tecture [24].
The COMP has previously designated orphan products
for the treatment of fragile X-syndrome, with the condi-
tion estimated to be affecting approximately 2 in 10,000
persons in the European Union, and being chronically
debilitating in particular due to neuro-behavioural and
neurodevelopmental symptoms including cognitive im-
pairment, anxiety, irritability, social withdrawal, inatten-
tion and hyperactivity, as well as epileptic seizures [25].
In a recent case of an application for the treatment of
Fragile-X syndrome which discussed in 2013, the spon-
sor presented data in a preclinical model of the condi-
tion using FMR1 deficient mice, as well as preliminary
clinical data in patients affected by the condition. With
regards to the clinical observations, the sponsor argued
improvements after treatment with the proposed prod-
uct based on symptom rating scales. The Committee
questioned the relevance of the endpoints used, and
considered that given the open nature of the studies and
the concomitant treatment with other psychotropic
medications, it would be difficult to draw conclusions at-
tributable to the proposed product. Moreover, a lack of
clarity regarding the mode of action of the proposed
product was identified. It was therefore considered that
the data included in the application were not sufficient
to justify the intention to treat the condition with the
applied product.
Discussion
The COMP assesses all applications submitted for orphan
desigantion on a case by case basis; it has to be noted that
the level, quality and quantity of data presented with eachapplication varies significantly. This depends on the par-
ticularities of the condition and product, as well as the
stage of development which may be at any point prior to
submitting a Marketing Authorisation Application. In
practice, the scientific support put forward may range
from a description of the assumed mode of action of a
product in the target condition to detailed analysis of end-
points from interventional studies in affected patients.
However, a generic scientific rationale, should generally be
further substantiated with specific data from the condition
as applied for designation, either in relevant models
(preclinical) or from patients with the disease, unless
the absence of such data can be adequately justified.
This expectation to provide data with the product in
the condition is clearly reflected in the updated rele-
vant guideline [2].
Accordingly, when reviewing the available data to jus-
tify medical plausibility, three main points are of particu-
lar importance; the availability of data with the specific
product as applied for designation, the relevance of the
non-clinical in vivo models or target patient population
used for the studies, and lastly the clinical relevance of
endpoints and results obtained. All of these aspects
contribute towards minimising the level of assumption
required, relative to the stage of development. Thus, a
balanced evaluation based on the level of evidence can
be made to allow for justification of the intention to
treat, diagnose or prevent a condition at the time of
designation. It could therefore be conceptualised that a
level of “maximum assumption level” relative to the
stage of development exists, above which the medical
plausibility cannot be accepted. This assumption level
may be reduced, if data with the product in the condi-
tion show meaningful improvements in relevant
endpoints.
The first prerequisite is to refer to a specific medicinal
product, which the sponsor is developing for a specific
orphan indication. Notwithstanding that a sponsor may
apply at any stage of development [1], it is usually the
case that the development of the specific product has
commenced and is underway. Hence, the sponsor should
have in general performed some non-clinical and/or pre-
liminary clinical studies with the proposed product as
applied for designation.
If no data are available with the proposed product
under review the level of assumption is so high, that ren-
ders the application by large “hypothetical”. As noted
above, the pharmacological target may present an oppor-
tunity based on strategy and scientific rationale in general,
but without any data with the specific product, the estab-
lishment of the orphan criteria is exceptionally difficult to
consider. In line with this notion, the Committee has pre-
viously requested in several procedures confirmation that
the product actually exists, and questioned whether it will
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sence of data in preclinical or clinical settings.
The second prerequisite would be the use of the spe-
cific product in a relevant non-clinical model and/or
preliminary clinical data in a target patient population
with the condition. The experience of the COMP with
regards to the potential and limitations of animal models
in the facilitation of drug development in rare diseases
has been previously discussed in the literature, where
models for metabolic, neuromuscular and ophthalmo-
logical orphan-designated conditions have been pre-
sented [13]. In the examples discussed above, it is also
pointed out that in the absence of such data the applica-
tions remain by large unsuccessful, because bridging to
data from other settings increases the assumption level
and weakens medical plausibility. However exceptionally,
if objective limitations can be documented the commit-
tee has considered such extrapolations.
Thirdly, clinically relevant endpoints are to be studied,
and the results obtained should be permissive of a clinic-
ally relevant intervention. In early stages of development,
the acceptability of endpoints may also be considered in
the context of a valid pathophysiologic pathway known to
be implicated in the disease. Moreover, even if appropriate
models or clinical settings are used, the results should still
be convincing to support the sought indication. The ex-
tent of effects should be clear and the observations have
to be confidently attributed to the product.
Conclusions
Based on the information from the COMP practice, as it
is reflected in the published minutes of its plenary meet-
ings, and in the context of the provisions of the orphan
framework and the relevant available guidance, there are
three points that in general need to be met in order to
justify the medical plausibility:
 data with the specific product as applied for
designation are required; the proposed product
exists and a stage of development can be identified;
 results from studies with the product are required in
either specific models of the condition, or in
patients affected by the condition as applied for
designation;
 the endpoints studied have to be clinically relevant
and the results adequate to allow for scientific
claims on improvement upon administration of the
product under review.
In conclusion, notwithstanding that the sponsors may
apply for orphan medicinal product designation in the EU
at any stage of development, the applications are expected
to include adequate data to support the proposal: the justifi-
cation of medical plausibility can be straightforward,provided that relevant results exist in the settings of the
specific condition and with the specific product as applied
for designation. Bridging of data from other products, or
other conditions than the one under review is by and large
not successful.
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